Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 458

Sort by

Sort Order Select

Journal Articles

Comparison of autologous HCT versus haploidentical donor HCT for Ph+ B-ALL patients following TKI therapy. a study from the global committee and the acute leukemia working party of the european society for blood and marrow transplantation

Blood (2025) 146 (Supplement 1): 6080.

https://doi.org/10.1182/blood-2025-6080

Published: 2025

Journal Articles

Venetoclax in combination with hypomethylating agents shows promising activity in Acute Myeloid Leukemia with late relapse post allogeneic stem cell transplant: From the EBMT acute leukemia working party

Blood (2025) 146 (Supplement 1): 6079.

https://doi.org/10.1182/blood-2025-6079

Published: 2025

Journal Articles

Young (35 years) matched sibling donors for allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT

Blood (2025) 146 (Supplement 1): 4193.

https://doi.org/10.1182/blood-2025-4193

Published: 2025

Journal Articles

Better outcomes with haploidentical than matched sibling donors for adult AML patients allo-transplanted in CR with detectable MRD: A study from the global committee and the ALWP of the EBMT.

Blood (2025) 146 (Supplement 1): 1059.

https://doi.org/10.1182/blood-2025-1059

Published: 2025

Journal Articles

Prognostic analysis of salvage allogeneic HCT in acute leukemia patients relapsing after autologous HCT: a study from the acute leukemia working party of the EBMT

Blood (2025) 146 (Supplement 1): 6041.

https://doi.org/10.1182/blood-2025-6041

Published: 2025

Journal Articles

Phase 1 evaluation of the safety and efficacy of rapcabtagene autoleucel (YTB323) in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Blood (2025) 146 (Supplement 1): 811.

https://doi.org/10.1182/blood-2025-811

Published: 2025

Journal Articles

The need for a subsequent HCT is a late & continuous risk and with significant impact in overall survival in haemoaglobinopathies: Real-world data from 2000–2022. an analysis of the european society for blood and marrow transplantation (EBMT) hemoglobinopathy working party.

Josu de la Fuente, Donatella Baronciani, Mathilde Fekom, Arnaud Dalissier, Marco Zecca, Franco Locatelli, Giorgio La Nasa, Raffaella Cerretti, Tariq Ghafoor, Giuseppe Visani, Hakan Ozdogu, Fabio Ciceri, Ashrafsadat Mousavi, Sandrine Bremathas, Selim Corbacioglu, Emanuele Angelucci

Blood (2025) 146 (Supplement 1): 178.

https://doi.org/10.1182/blood-2025-178

Published: 2025

Journal Articles

The impact of additional cytogenetic abnormalities and complex karyotype on outcomes of adult patients with Philadelphia-positive acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in first complete remission: A study from the ALWP/EBMT

Blood (2025) 146 (Supplement 1): 6067.

https://doi.org/10.1182/blood-2025-6067

Published: 2025

Journal Articles

Outcomes of 544 patients with t(6;9) Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation: An EBMT Study on behalf of the acute leukemia working party (ALWP) and the pediatric diseases working party (PDWP)

Blood (2025) 146 (Supplement 1): 6066.

https://doi.org/10.1182/blood-2025-6066

Published: 2025

Journal Articles

Real world outcomes of FLT3 inhibitors and hypomethylating agents as post transplant prophylaxis in Acute Myeloid Leukemia patients transplanted in first complete remission: From the EBMT acute leukemia working party

Blood (2025) 146 (Supplement 1): 4279.

https://doi.org/10.1182/blood-2025-4279

Published: 2025

Journal Articles

Allo-HCT outcomes for AML patients with NUP98 rearrangements: A study on behalf of the global committee, the ALWP and the PDWP of the EBMT

Blood (2025) 146 (Supplement 1): 4270.

https://doi.org/10.1182/blood-2025-4270

Published: 2025

Journal Articles

Improved survival in Philadelphia Chromosome–Positive acute lymphoblastic leukemia with pre-transplant second- and third-generation TKIs and post-transplant prophylactic maintenance: A study from the EBMT ALWP

Blood (2025) 146 (Supplement 1): 6290.

https://doi.org/10.1182/blood-2025-6290

Published: 2025

Journal Articles

Allogeneic stem cell transplantation with post-transplantation cyclophosphamide in patients with acute myeloid leukemia achieving first complete remission after one versus two inductions: A study from the ALWP/EBMT

Blood (2025) 146 (Supplement 1): 4288.

https://doi.org/10.1182/blood-2025-4288

Published: 2025

Journal Articles

Metabolic signatures mirror divergent modalities of leukemia immune evasion and relapse after transplantation

Annalisa Tameni, Emanuele Rondelli, Angela Gentile, Vittorio Niccolucci, Maria Chiara Di Bonito, Fatemeh Kordevani, Francesca Tortorelli, Simone Cardaci, Raffaella Di Micco, Dejan Lazarevic, Giovanni Tonon, David Sumpton, Alejandro Huerta Uribe, Marco Punta, Cristina Toffalori, Fabio Ciceri, Luca Vago

Blood (2025) 146 (Supplement 1): 590.

https://doi.org/10.1182/blood-2025-590

Published: 2025

Journal Articles

Anti-CD19 chimeric antigen receptor T-cells therapy (CAR-T) is effective in secondary cns lymphoma (SCNSL) refractory to high-dose methotrexate (HDMTX)-based chemotherapy

Blood (2025) 146 (Supplement 1): 7241.

https://doi.org/10.1182/blood-2025-7241

Published: 2025

Journal Articles

Impact of thiotepa dose in haploidentical allogeneic stem cell transplantation with thiotepa-busulfan-fludarabine conditioning for Acute Myeloid Leukemia in remission: A retrospective analysis of the EBMT acute leukemia working party

Blood (2025) 146 (Supplement 1): 5980.

https://doi.org/10.1182/blood-2025-5980

Published: 2025

Journal Articles

Impact of NRAS and/or KRAS mutations on post-transplant outcomes in Acute Myeloid Leukemia: A study on behalf of EBMT-ALWP

Blood (2025) 146 (Supplement 1): 6395.

https://doi.org/10.1182/blood-2025-6395

Published: 2025

Journal Articles

Lentiviral hematopoietic stem and progenitor cell gene therapy with Etuvetidigene autotemcel for the treatment of Wiskott-Aldrich Syndrome

Blood (2025) 146 (Supplement 1): 6092.

https://doi.org/10.1182/blood-2025-6092

Published: 2025

Journal Articles

Cytomegalovirus (CMV) reactivation negatively impacts survival after CAR T-cell therapy in lymphoma patients: Results from the CART-SIE study

Blood (2025) 146 (Supplement 1): 3722.

https://doi.org/10.1182/blood-2025-3722

Published: 2025

Journal Articles

T cell replete haploidentical transplantation compared to mismatched unrelated allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT

Blood (2025) 146 (Supplement 1): 114.

https://doi.org/10.1182/blood-2025-114

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Comparison of autologous HCT versus haploidentical donor HCT for Ph+ B-ALL patients following TKI therapy. a study from the global committee and the acute leukemia working party of the european society for blood and marrow transplantation

Venetoclax in combination with hypomethylating agents shows promising activity in Acute Myeloid Leukemia with late relapse post allogeneic stem cell transplant: From the EBMT acute leukemia working party

Young (35 years) matched sibling donors for allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT

Better outcomes with haploidentical than matched sibling donors for adult AML patients allo-transplanted in CR with detectable MRD: A study from the global committee and the ALWP of the EBMT.

Prognostic analysis of salvage allogeneic HCT in acute leukemia patients relapsing after autologous HCT: a study from the acute leukemia working party of the EBMT

Phase 1 evaluation of the safety and efficacy of rapcabtagene autoleucel (YTB323) in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

The need for a subsequent HCT is a late & continuous risk and with significant impact in overall survival in haemoaglobinopathies: Real-world data from 2000–2022. an analysis of the european society for blood and marrow transplantation (EBMT) hemoglobinopathy working party.

The impact of additional cytogenetic abnormalities and complex karyotype on outcomes of adult patients with Philadelphia-positive acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in first complete remission: A study from the ALWP/EBMT

Outcomes of 544 patients with t(6;9) Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation: An EBMT Study on behalf of the acute leukemia working party (ALWP) and the pediatric diseases working party (PDWP)

Real world outcomes of FLT3 inhibitors and hypomethylating agents as post transplant prophylaxis in Acute Myeloid Leukemia patients transplanted in first complete remission: From the EBMT acute leukemia working party

Allo-HCT outcomes for AML patients with NUP98 rearrangements: A study on behalf of the global committee, the ALWP and the PDWP of the EBMT

Improved survival in Philadelphia Chromosome–Positive acute lymphoblastic leukemia with pre-transplant second- and third-generation TKIs and post-transplant prophylactic maintenance: A study from the EBMT ALWP

Allogeneic stem cell transplantation with post-transplantation cyclophosphamide in patients with acute myeloid leukemia achieving first complete remission after one versus two inductions: A study from the ALWP/EBMT

Metabolic signatures mirror divergent modalities of leukemia immune evasion and relapse after transplantation

Anti-CD19 chimeric antigen receptor T-cells therapy (CAR-T) is effective in secondary cns lymphoma (SCNSL) refractory to high-dose methotrexate (HDMTX)-based chemotherapy

Impact of thiotepa dose in haploidentical allogeneic stem cell transplantation with thiotepa-busulfan-fludarabine conditioning for Acute Myeloid Leukemia in remission: A retrospective analysis of the EBMT acute leukemia working party

Impact of NRAS and/or KRAS mutations on post-transplant outcomes in Acute Myeloid Leukemia: A study on behalf of EBMT-ALWP

Lentiviral hematopoietic stem and progenitor cell gene therapy with Etuvetidigene autotemcel for the treatment of Wiskott-Aldrich Syndrome

Cytomegalovirus (CMV) reactivation negatively impacts survival after CAR T-cell therapy in lymphoma patients: Results from the CART-SIE study

T cell replete haploidentical transplantation compared to mismatched unrelated allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only